Antagonistic effect of insulin-like growth factor I on protein kinase inhibitor—mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-x-L
- 1 May 1998
- journal article
- research article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 88 (5) , 884-889
- https://doi.org/10.3171/jns.1998.88.5.0884
Abstract
Object. Tamoxifen (TAM) has been found to be effective in inhibiting proliferation of glioblastoma cells in vitro, but clinical studies have been disappointing. The purpose of this study was to determine whether insulin-like growth factor I (IGF-I), a potential autocrine/paracrine mitogen produced by glioblastomas, interferes with the antimitogenic actions of TAM. Methods. Human glioblastoma cells were treated with or without TAM and/or IGF-I in vitro and evaluated for: viability by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide cleavage assay; apoptosis by histochemical analysis of nuclear morphology and 3′-OH DNA fragments; and expression of the IGF-I receptor, and the bcl-2, bcl-xL, and bax proteins by immunoblot analysis. In addition, p53 status was determined by DNA sequencing and by transient transfection with luciferase reporter plasmids containing wild-type or mutant p53. Results indicated that after 72 hours of exposure to 2 mg/ml TAM in vitro, 56.3% of WITG3 and 43.8% of U87-MG glioblastoma cells contained apoptotic nuclei (p < 0.01 compared with untreated cells). Apoptosis was independent of the presence of p53 because the WITG3 cells, in contrast to the U87-MG cells, expressed a mutant, nonfunctional p53. The WITG3 cells expressed IGF-I receptor proteins and demonstrated IGF-I binding. Exogenous IGF-I stimulated WITG3 cell proliferation and significantly (p < 0.05) antagonized the cytotoxic effects of TAM in a dose-dependent fashion; IGF-I, but not TAM, enhanced expression of bcl-2 and bcl-xL proteins; however, bax protein expression was unchanged by either treatment. Conclusions. Because many gliomas secrete large amounts of IGF-I in autocrine/paracrine growth pathways, these data may, in part, explain the failure of TAM to achieve clinical results as dramatic as those in vitro.Keywords
This publication has 17 references indexed in Scilit:
- Insulin-Like Growth Factor-1 Inhibition of Apoptosis Is Associated with Increased Expression of the bcl-xL Gene ProductEndocrinology, 1997
- Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells.Journal of Clinical Investigation, 1994
- Protein kinase C inhibitors induce apoptosis in human malignant glioma cell linesFEBS Letters, 1994
- Expression and function of the insulin‐like growth factor I system in human non‐small‐cell lung cancer and normal lung cell linesInternational Journal of Cancer, 1994
- p53 Mutations are common in pancreatic cancer and are absent in chronic pancreatitisCancer Letters, 1993
- Clinical and Radiographic Response in a Minority of Patients with Recurrent Malignant Gliomas Treated with High-Dose TamoxifenNeurosurgery, 1993
- Nicotinic Agonists, Phorbol Esters, and Growth Factors Activate Two Extracellular Signal‐Regulated Kinases, ERK1 and ERK2, in Bovine Chromaffin CellsJournal of Neurochemistry, 1992
- Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitroNeurosurgery, 1991
- Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C systemJournal of Neurosurgery, 1990
- Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathwaysJournal of Neurosurgery, 1990